Inventiva (IVA) Cash from Investing Activities (2019 - 2025)
Inventiva's (IVA) quarterly Cash from Investing Activities came in at -$28.1 million in Q2 2025, down 10166.56% quarter-over-quarter from -$273426.3 in Q4 2022.
Inventiva (IVA) Cash from Investing Activities (2019 - 2025) Analysis & Trends
Inventiva's Cash from Investing Activities history runs 5 years deep, the most recent figure standing at -$28.1 million for Q2 2025.
- On a quarterly basis, Cash from Investing Activities changed N/A year-over-year to -$28.1 million in Q2 2025; TTM through Jun 2025 was -$23.2 million, a N/A change from a year earlier, with the FY2025 full-year figure at -$155.1 million, down 1759.21% from the prior year.
- Cash from Investing Activities slipped to -$28.1 million in Q2 2025 per IVA's latest filing, from -$273426.3 in the prior quarter.
- Across five years, Cash from Investing Activities topped out at $7.7 million in Q1 2021 and bottomed at -$28.1 million in Q2 2025.
- The 3-year median for Cash from Investing Activities is -$276534.1 (2022), against an average of -$2.9 million.
- Across the five-year window, Cash from Investing Activities surged 553.88% in 2021 and tumbled 105.04% in 2022, its largest moves.
- Year by year, Cash from Investing Activities stood at $5.4 million in 2021, then tumbled by 105.04% to -$273426.3 in 2022, then slumped by 10166.56% to -$28.1 million in 2025.
- Per Business Quant, the three latest IVA Cash from Investing Activities figures stand at -$28.1 million (Q2 2025), -$273426.3 (Q4 2022), and -$279641.8 (Q3 2022).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,921.77 Bn | 66,921.49 Bn | - | - |
| 2 | Nanobiotix | 1,911.83 Bn | 1,911.77 Bn | - | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - | - |
| 4 | BeOne Medicines | 471.57 Bn | 466.77 Bn | 1.35 Bn | -45.51 Mn |
| 5 | Vertex Pharmaceuticals | 122.01 Bn | 114.76 Bn | 2.59 Bn | -431.90 Mn |
| 6 | Regeneron Pharmaceuticals | 70.09 Bn | 61.34 Bn | 3.31 Bn | -428.90 Mn |
| 7 | Belite Bio | 62.68 Bn | 62.68 Bn | - | - |
| 8 | Argenx Se | 55.86 Bn | 50.68 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.48 Bn | 34.47 Bn | 959.66 Mn | -25.54 Mn |
| 10 | Inventiva | 849.95 Mn | 849.95 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | -28.07 Mn |
| Jun 30, 2025 | -28.07 Mn |
| Dec 31, 2022 | -273,426.29 |
| Dec 31, 2022 | -273,426.29 |
| Sep 22, 2022 | -279,641.81 |
| Sep 22, 2022 | -279,641.81 |
| Dec 31, 2021 | 5.42 Mn |
| Dec 31, 2021 | 5.42 Mn |
| Jun 30, 2021 | -1.97 Mn |
| Jun 30, 2021 | -1.97 Mn |
| Mar 31, 2021 | 7.69 Mn |
| Mar 31, 2021 | 7.69 Mn |
| Dec 31, 2020 | -1.19 Mn |
| Dec 31, 2020 | -1.19 Mn |
| Dec 31, 2019 | -928,678.76 |
| Dec 31, 2019 | -928,678.76 |